Identification of Cyclin B1 As a Shared Human Epithelial Tumor-associated Antigen Recognized by T Cells

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2001 Nov 7

PMID 11696596

Citations 52

Authors

H Kao

J A Marto

T K Hoffmann

J Shabanowitz

S D Finkelstein

T L Whiteside

D F Hunt

O J Finn

Affiliations

Soon will be listed here.

Abstract

We eluted peptides from class I molecules of HLA-A2.1(+) breast adenocarcinoma and loaded reverse phase high-performance liquid chromatography (HPLC) fractions onto dendritic cells to prime naive CD8(+) T cells. Fractions that supported growth of tumor-specific cytotoxic T lymphocytes were analyzed by nano-HPLC micro-ESI tandem mass spectrometry. Six HLA-A2.1-binding peptides, four 9-mers (P1-P4) differing in the COOH-terminal residue, and two 10-mers (P5 and P6) with an additional COOH-terminal alanine, were identified in one fraction. Peptide sequences were homologous to cyclin B1. We primed CD8(+) T cells from another HLA-A2.1(+) healthy donor with synthetic peptides and generated P4-specific responses. We also detected memory T cells specific for one or more of these peptides in patients with breast cancer and squamous cell carcinomas of the head and neck (SCCHN). T cells from one patient, restimulated once in vitro, could kill the tumor cell line from which the peptides were derived. Immunohistochemical analysis of tumor lines and tissue sections showed cyclin B1 overexpression and aberrant localization in the cytoplasm instead of the nucleus. Sequencing genomic DNA and cDNA corresponding to P1-P6 region showed that differences in COOH-terminal residues were not due to either DNA mutations or errors in transcription, suggesting a high error rate in translation of cyclin B1 protein in tumors.

Citing Articles

Proapoptotic role of CDK1 in overcoming paclitaxel resistance in ovarian cancer cells in response to combined treatment with paclitaxel and duloxetine.

Kim G, Jang S, Ahn S, Kim S, Park C, Seong M Cancer Cell Int. 2024; 24(1):409.

PMID: 39702300 PMC: 11660910. DOI: 10.1186/s12935-024-03607-8.

KCNN1 promotes proliferation and metastasis of breast cancer via ERLIN2-mediated stabilization and K63-dependent ubiquitination of Cyclin B1.

Xiao B, Xiang Q, Deng Z, Chen D, Wu S, Zhang Y Carcinogenesis. 2023; 44(12):809-823.

PMID: 37831636 PMC: 10818095. DOI: 10.1093/carcin/bgad070.

CCNB1 is a novel prognostic biomarker and promotes proliferation, migration and invasion in Wilms tumor.

Xiang B, Chen M, Gao Z, Mi T, Shi Q, Dong J BMC Med Genomics. 2023; 16(1):189.

PMID: 37592341 PMC: 10433552. DOI: 10.1186/s12920-023-01627-3.

Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens.

Schossig P, Coskun E, Arsenic R, Horst D, Sehouli J, Bergmann E Int J Mol Sci. 2023; 24(3).

PMID: 36768616 PMC: 9916968. DOI: 10.3390/ijms24032292.

LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors.

Jacqueline C, Dracz M, Xue J, Binder R, Minden J, Finn O Oncoimmunology. 2022; 11(1):2029083.

PMID: 35083098 PMC: 8786340. DOI: 10.1080/2162402X.2022.2029083.

References

Coulie P, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C . A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994; 180(1):35-42. PMC: 2191574. DOI: 10.1084/jem.180.1.35. View

Wang R, Wang X, ATWOOD A, Topalian S, Rosenberg S . Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 1999; 284(5418):1351-4. DOI: 10.1126/science.284.5418.1351. View

Martin S, Shabanowitz J, Hunt D, Marto J . Subfemtomole MS and MS/MS peptide sequence analysis using nano-HPLC micro-ESI fourier transform ion cyclotron resonance mass spectrometry. Anal Chem. 2000; 72(18):4266-74. DOI: 10.1021/ac000497v. View

Traversari C, van der Bruggen P, Luescher I, Lurquin C, Chomez P, Van Pel A . A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992; 176(5):1453-7. PMC: 2119413. DOI: 10.1084/jem.176.5.1453. View

Shively J, Beatty J . CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hematol. 1985; 2(4):355-99. DOI: 10.1016/s1040-8428(85)80008-1. View

Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, De Plaen E . A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995; 269(5228):1281-4. DOI: 10.1126/science.7652577. View

Ropke M, Hald J, Guldberg P, Zeuthen J, Norgaard L, Fugger L . Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A. 1996; 93(25):14704-7. PMC: 26199. DOI: 10.1073/pnas.93.25.14704. View

Henderson R, Finn O . Human tumor antigens are ready to fly. Adv Immunol. 1996; 62:217-56. DOI: 10.1016/s0065-2776(08)60431-9. View

Tureci O, Sahin U, Pfreundschuh M . Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today. 1997; 3(8):342-9. DOI: 10.1016/s1357-4310(97)01081-2. View

10.

Zeh 3rd H, Leder G, Lotze M, Salter R, Tector M, Stuber G . Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol. 1994; 39(2):79-86. DOI: 10.1016/0198-8859(94)90105-8. View

11.

Soria J, Jang S, Khuri F, Hassan K, Liu D, Hong W . Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 2000; 60(15):4000-4. View

12.

Yasumura S, Hirabayashi H, Schwartz D, Toso J, Johnson J, Herberman R . Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res. 1993; 53(6):1461-8. View

13.

Fisk B, Blevins T, Wharton J, Ioannides C . Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995; 181(6):2109-17. PMC: 2192068. DOI: 10.1084/jem.181.6.2109. View

14.

Finn O, Jerome K, Henderson R, Pecher G, Domenech N, Barratt-Boyes S . MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev. 1995; 145:61-89. DOI: 10.1111/j.1600-065x.1995.tb00077.x. View

15.

Ressing M, Sette A, BRANDT R, Ruppert J, Wentworth P, Hartman M . Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 1995; 154(11):5934-43. View

16.

Lennette E, Winberg G, Yadav M, Enblad G, Klein G . Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer. 1995; 31A(11):1875-8. DOI: 10.1016/0959-8049(95)00354-l. View

17.

Herr W, Schneider J, Lohse A, Meyer zum Buschenfelde K, Wolfel T . Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods. 1996; 191(2):131-42. DOI: 10.1016/0022-1759(96)00007-5. View

18.

Keyomarsi K, Pardee A . Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A. 1993; 90(3):1112-6. PMC: 45821. DOI: 10.1073/pnas.90.3.1112. View

19.

Clauser K, Baker P, Burlingame A . Role of accurate mass measurement (+/- 10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal Chem. 1999; 71(14):2871-82. DOI: 10.1021/ac9810516. View

20.

Wang A, Yoshimi N, Ino N, Tanaka T, Mori H . Overexpression of cyclin B1 in human colorectal cancers. J Cancer Res Clin Oncol. 1997; 123(2):124-7. DOI: 10.1007/BF01269891. View